person reading

About BridgeBio Pharma Inc - Company Information, Overview, History and Profile

What does BridgeBio Pharma Inc do?

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

BridgeBio Pharma Inc Management structure

All Gross Remunerations are in USD
Dr. Neil Kumar, PhD
Director and Chief Executive Officer of the Company and Eidos Therapeutics, Inc.
-
2024
Gross Remuneration
Year
Dr. Thomas Trimarchi, PhD
Principal Financial Officer, President and Chief Operating Officer
-
2024
Gross Remuneration
Year
Dr. Brian C. Stephenson, PhD
Secretary, Chief Financial Officer and Principal Accounting Officer
-
2024
Gross Remuneration
Year
Ms. Maricel M. Apuli
Chief Accounting Officer
-
2024
Gross Remuneration
Year

BridgeBio Pharma Inc Board of directors

All Gross Remunerations are in USD
Dr. Neil Kumar, PhD
Director and Chief Executive Officer of the Compan
-
2024
Gross Remuneration
Year
Dr. Charles J. Homcy,M.D.
Lead Independent Director and Chairman of Pharmace
-
2024
Gross Remuneration
Year
Mr. Fred Hassan
Independent Director
-
2024
Gross Remuneration
Year
Mr. James C. Momtazee
Independent Director
-
2024
Gross Remuneration
Year
Dr. Randal W. Scott,PhD
Independent Director
-
2024
Gross Remuneration
Year
Dr. Frank P. McCormick, D.Sc.
Director
-
2024
Gross Remuneration
Year